Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," ...

The average age of men who get diagnosed is 67.

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...

One type of androgen deprivation therapy may speed coronary plaque growth in men being treated for localized prostate cancer.

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

Focal therapy now helping in the fight against prostate cancer With focal therapy, doctors are now able to destroy cancer cells without damaging the surrounding nerves and tissue. In today’s ...

As Candel Therapeutics gears up for a planned U.S. approval push for its prostate cancer drug later this year, RTW ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy. When blocked, these enzymes cause the androgen receptor to collapse, ...